Alpha 2.0
Login Register
» Articles » PMID: 33564446

Relapse of Membranous Nephropathy with Cancer Immunotherapy

Overview
Journal Clin Kidney J
Publisher Oxford University Press
Specialty Nephrology
Date 2021 Feb 10
PMID 33564446
Citations 8
Authors
Youngho Kim
Affiliations
Soon will be listed here.
Abstract

Advances in monoclonal antibody technology have enabled the application of engineered antibodies to interfere with specific immune pathways. Checkpoint inhibitors have shown promising results in treating certain cancers by employing patients' own immune systems to attack cancer cells. Checkpoint inhibitors release the brake on the immune system and can cause immune-related diseases. Theoretically this could be disadvantageous in patients with autoimmune diseases. Here I describe a case of nephrotic syndrome relapse in a patient with a history of membranous nephropathy during programmed death-ligand 1 inhibitor therapy for lung cancer. It is postulated that enhancement of the immune system triggered the relapse of nephrotic syndrome by leading to an escape of immune tolerance and increased susceptibility.

Citing Articles

Membranous Nephropathy as a Paraneoplastic Syndrome in Cancer of Unknown Primary.

Kaira K, Amano H, Imai H, Okada H, Kagamu H In Vivo. 2024; 38(3):1503-1508.

PMID: 38688636 PMC: 11059915. DOI: 10.21873/invivo.13598.

A lung squamous cell carcinoma-associated membranous nephropathy patient free of tumor and membranous nephropathy after the treatment of surgery and radiochemotherapy following pembrolizumab: A rare case report.

Chen F, Du H, Fang S Medicine (Baltimore). 2023; 102(3):e32508.

PMID: 36701715 PMC: 9857441. DOI: 10.1097/MD.0000000000032508.

Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?.

He X, Liu F, Jin Y, Fu H, Mao J Ren Fail. 2022; 44(1):2046-2055.

PMID: 36420664 PMC: 9704066. DOI: 10.1080/0886022X.2022.2147439.

Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.

Gerard A, Barbosa S, Parassol N, Andreani M, Merino D, Cremoni M Clin Kidney J. 2022; 15(10):1881-1887.

PMID: 36158153 PMC: 9494514. DOI: 10.1093/ckj/sfac109.

Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.

Ratanasrimetha P, Reddy V, Kala J, Tchakarov A, Glass W, Msaouel P Front Immunol. 2022; 13:898811.

PMID: 35967405 PMC: 9366044. DOI: 10.3389/fimmu.2022.898811.

References
1.
Laluck Jr B, Cattran D . Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis. 1999; 33(6):1026-32. DOI: 10.1016/S0272-6386(99)70138-1. View
2.
Grywalska E, Smarz-Widelska I, Krasowska-Zajac E, Korona-Glowniak I, Zaluska-Patel K, Mielnik M . The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides. Arch Immunol Ther Exp (Warsz). 2017; 66(2):133-143. PMC: 5851708. DOI: 10.1007/s00005-017-0485-3. View
3.
Wanchoo R, Karam S, Uppal N, Barta V, Deray G, Devoe C . Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol. 2017; 45(2):160-169. DOI: 10.1159/000455014. View
4.
Timmermans S, Ayalon R, van Paassen P, Beck Jr L, van Rie H, Wirtz J . Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis. 2013; 62(6):1223-5. DOI: 10.1053/j.ajkd.2013.07.019. View
5.
Menke J, Lucas J, Zeller G, Keir M, Huang X, Tsuboi N . Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol. 2007; 179(11):7466-77. DOI: 10.4049/jimmunol.179.11.7466. View